Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Matthay, C. Reynolds, R. Seeger, H. Shimada, E. Adkins, D. Haas-Kogan, R. Gerbing, W. London, J. Villablanca (2009)
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 7
Tangying Lu, R. Ramakrishnan, S. Altiok, Je-in Youn, P. Cheng, E. Celis, V. Pisarev, Simon Sherman, M. Sporn, D. Gabrilovich (2011)
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.The Journal of clinical investigation, 121 10
Minka Dongen, N. Savage, E. Jordanova, I. Bruijn, Kimberley Walburg, T. Ottenhoff, P. Hogendoorn, S. Burg, H. Gelderblom, T. Hall (2010)
Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumorsInternational Journal of Cancer, 127
H. Moore, K. Wood, M. Jackson, M. Lastowska, D. Hall, H. Imrie, C. Redfern, P. Lovat, F. Ponthan, K. O'toole, J. Lunec, D. Tweddle (2008)
Histological profile of tumours from MYCN transgenic miceJournal of Clinical Pathology, 61
F. Morandi, S. Chiesa, P. Bocca, E. Millo, A. Salis, M. Solari, V. Pistoia, I. Prigione (2006)
Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.Neoplasia, 8 10
Tao Liu, A. Tee, Antonio Porro, Stewart Smith, Tanya Dwarte, Pei Liu, N. Iraci, E. Sekyere, M. Haber, M. Norris, Daniel Diolaiti, G. Valle, G. Perini, G. Marshall (2007)
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesisProceedings of the National Academy of Sciences, 104
S. Asgharzadeh, J. Salo, Lingyun Ji, A. Oberthuer, M. Fischer, F. Berthold, Michael Hadjidaniel, C. Liu, L. Metelitsa, R. Pique-Regi, Peter Wakamatsu, J. Villablanca, S. Kreissman, K. Matthay, H. Shimada, W. London, R. Sposto, R. Seeger (2012)
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
I. Prigione, M. Corrias, I. Airoldi, L. Raffaghello, F. Morandi, P. Bocca, C. Cocco, S. Ferrone, V. Pistoia (2004)
Immunogenicity of Human NeuroblastomaAnnals of the New York Academy of Sciences, 1028
C. Burkhart, Andy Cheng, J. Madafiglio, M. Kavallaris, Mario Mili, G. Marshall, W. Weiss, L. Khachigian, M. Norris, M. Haber (2003)
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.Journal of the National Cancer Institute, 95 18
C. Chung, T. Boterberg, J. Lucas, J. Panoff, D. Valteau‐Couanet, B. Hero, R. Bagatell, C. Hill-Kayser (2007)
NeuroblastomaThe Lancet, 369
A. Yu, A. Gilman, M. Ozkaynak, W. London, S. Kreissman, Helen Chen, Malcolm Smith, B. Anderson, J. Villablanca, K. Matthay, H. Shimada, S. Grupp, R. Seeger, C. Reynolds, A. Buxton, R. Reisfeld, S. Gillies, S. Cohn, J. Maris, P. Sondel (2010)
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.The New England journal of medicine, 363 14
Teeara Berry, W. Luther, Namrata Bhatnagar, Y. Jamin, E. Poon, T. Sanda, Desheng Pei, Bandana Sharma, Winston Vetharoy, A. Hallsworth, Zai Ahmad, K. Barker, L. Moreau, H. Webber, Wen-chao Wang, Qingsong Liu, A. Perez-Atayde, S. Rodig, N. Cheung, F. Raynaud, B. Hallberg, S. Robinson, N. Gray, A. Pearson, S. Eccles, L. Chesler, R. George (2012)
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.Cancer cell, 22 1
J. Stauffer, R. Orentas, Erin Lincoln, T. Khan, R. Salcedo, J. Hixon, T. Back, Jun Wei, R. Patidar, Young Song, Laura Hurd, M. Tsokos, E. Lai, G. Eisenhofer, W. Weiss, Javed Khan, J. Wigginton (2012)
High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug DiscoveryCancer Investigation, 30
David Delgado, J. Hank, J. Kolesar, D. Lorentzen, J. Gan, S. Seo, KyungMann Kim, S. Shusterman, S. Gillies, R. Reisfeld, Richard Yang, B. Gadbaw, K. Desantes, W. London, R. Seeger, J. Maris, P. Sondel (2010)
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.Cancer research, 70 23
N. Cheung, R. Sowers, A. Vickers, I. Cheung, B. Kushner, R. Gorlick (2006)
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18
N. Huebener, S. Fest, A. Strandsby, Elke Michalsky, R. Preissner, Yan Zeng, G. Gaedicke, H. Lode (2008)
A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunityMolecular Cancer Therapeutics, 7
S. Shusterman, W. London, S. Gillies, J. Hank, Stephan Voss, R. Seeger, C. Reynolds, J. Kimball, M. Albertini, B. Wagner, J. Gan, J. Eickhoff, Kenneth DeSantes, Susan Cohn, T. Hecht, B. Gadbaw, Ralph Reisfeld, John Maris, P. Sondel (2010)
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 33
S. Ash, J. Stein, N. Askenasy, I. Yaniv (2010)
Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantationBritish Journal of Cancer, 103
W. Norde, F. Maas, W. Hobo, A. Korman, M. Quigley, M. Kester, K. Hebeda, J. Falkenburg, N. Schaap, T. Witte, R. Voort, H. Dolstra (2011)
PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.Cancer research, 71 15
R. Seeger, G. Brodeur, H. Sather, A. Dalton, S. Siegel, K. Wong, D. Hammond (1985)
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.The New England journal of medicine, 313 18
D. Valteau‐Couanet, C. Leboulaire, K. Maincent, M. Tournier, O. Hartmann, J. Bénard, F. Beaujean, C. Boccaccio, L. Zitvogel, E. Angevin (2002)
Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.Blood, 100 7
Christopher Hackett, J. Hodgson, M. Law, J. Fridlyand, K. Osoegawa, P. Jong, N. Nowak, D. Pinkel, D. Albertson, Ajay Jain, R. Jenkins, J. Gray, W. Weiss (2003)
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.Cancer research, 63 17
Marta Terrile, K. Bryan, L. Vaughan, A. Hallsworth, H. Webber, L. Chesler, R. Stallings (2011)
miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAsPLoS ONE, 6
S. Haraguchi, A. Nakagawara (2009)
A Simple PCR Method for Rapid Genotype Analysis of the TH-MYCN Transgenic MousePLoS ONE, 4
J. Jacobs, F. Brasseur, C. Kaa, M. Rakt, C. Figdor, G. Adema, P. Hoogerbrugge, P. Coulie, I. Vries (2007)
Cancer‐germline gene expression in pediatric solid tumors using quantitative real‐time PCRInternational Journal of Cancer, 120
J. Venstrom, Junting Zheng, N. Noor, K. Danis, Alice Yeh, I. Cheung, B. DuPont, R. O'reilly, N. Cheung, K. Hsu (2009)
KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk NeuroblastomaClinical Cancer Research, 15
L. Raffaghello, I. Prigione, I. Airoldi, M. Camoriano, I. Levreri, C. Gambini, D. Pende, A. Steinle, S. Ferrone, V. Pistoia (2004)
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.Neoplasia, 6 5
C. Coughlin, M. Fleming, R. Carroll, B. Pawel, M. Hogarty, Xiaochuan Shan, B. Vance, Jarish Cohen, S. Jairaj, E. Lord, Michael Wexler, G. Danet-Desnoyers, J. Pinkus, G. Pinkus, J. Maris, S. Grupp, R. Vonderheide (2006)
Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 36
N. Tarek, Jean-Benoît Luduec, M. Gallagher, Junting Zheng, J. Venstrom, Elizabeth Chamberlain, S. Modak, G. Heller, B. DuPont, N. Cheung, K. Hsu (2012)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.The Journal of clinical investigation, 122 9
Sandra Acosta, C. Lavarino, R. París, I. García, C. Torres, E. Rodríguez, H. Beleta, J. Mora (2009)
Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cellsBMC Developmental Biology, 9
Holger Lode, Rong Xiang, C. Dolman, Ralph Reisfeld, N. Varki, S. Gillies (1997)
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.Journal of the National Cancer Institute, 89 21
C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, T. Allen, V. Pistoia, M. Ponzoni (2004)
Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.Journal of the National Cancer Institute, 96 15
K. Kramer, W. Gerald, B. Kushner, S. Larson, Meera Hameed, N. Cheung (1998)
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 9
Goleeta Alam, H. Cui, Huilin Shi, Liqun Yang, Jane Ding, L. Mao, W. Maltese, H. Ding (2009)
MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.The American journal of pathology, 175 2
Andy Cheng, N. Cheng, J. Ford, Janice Smith, Jayne Murray, C. Flemming, M. Lastowska, M. Jackson, Christopher Hackett, W. Weiss, G. Marshall, U. Kees, M. Norris, M. Haber (2007)
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.European journal of cancer, 43 9
Weiqing Jing, Xiaocai Yan, W. Hallett, J. Gershan, Bryon Johnson (2011)
Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma.Blood, 117 25
Bryon Johnson, Weiqing Jing, R. Orentas (2007)
CD25+ Regulatory T Cell Inhibition Enhances Vaccine-induced Immunity to NeuroblastomaJournal of Immunotherapy, 30
L. Raffaghello, I. Prigione, I. Airoldi, M. Camoriano, F. Morandi, P. Bocca, C. Gambini, S. Ferrone, V. Pistoia (2005)
Mechanisms of immune evasion of human neuroblastoma.Cancer letters, 228 1-2
L. Hansford, W. Thomas, J. Keating, C. Burkhart, A. Peaston, M. Norris, M. Haber, P. Armati, W. Weiss, G. Marshall (2004)
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.Proceedings of the National Academy of Sciences of the United States of America, 101 34
I. Airoldi, S. Lualdi, S. Bruno, L. Raffaghello, M. Occhino, C. Gambini, V. Pistoia, M. Corrias (2003)
Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40LBritish Journal of Cancer, 88
A. Swarbrick, S. Woods, A. Shaw, A. Balakrishnan, Yuwei Phua, A. Nguyen, Yvan Chanthery, Lionel Lim, L. Ashton, Robert Judson, N. Huskey, R. Blelloch, M. Haber, M. Norris, P. Lengyel, Christopher Hackett, T. Preiss, A. Chetcuti, C. Sullivan, E. Marcusson, W. Weiss, N. L’Etoile, A. Goga (2010)
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaNature Medicine, 16
M. Wölfl, A. Jungbluth, F. Garrido, T. Cabrera, Sharon Meyen-Southard, R. Spitz, K. Ernestus, F. Berthold (2005)
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastomaCancer Immunology, Immunotherapy, 54
T. Teitz, Jennifer Stanke, Sara Federico, Cori Bradley, R. Brennan, Jiakun Zhang, Melissa Johnson, J. Sedlacik, Madoka Inoue, Ziwei Zhang, S. Frase, J. Rehg, C. Hillenbrand, D. Finkelstein, C. Calabrese, M. Dyer, J. Lahti (2011)
Preclinical Models for Neuroblastoma: Establishing a Baseline for TreatmentPLoS ONE, 6
L. Raffaghello, I. Prigione, P. Bocca, F. Morandi, M. Camoriano, C. Gambini, Xinhui Wang, S. Ferrone, V. Pistoia (2005)
Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implicationsOncogene, 24
W. Weiss, Ken Aldape, G. Mohapatra, B. Feuerstein, J. Bishop (1997)
Targeted expression of MYCN causes neuroblastoma in transgenic miceThe EMBO Journal, 16
Je-in Youn, S. Nagaraj, Michelle Collazo, D. Gabrilovich (2008)
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1The Journal of Immunology, 181
M. Corrias, M. Occhino, M. Croce, A. Ambrosis, M. Pistillo, P. Bocca, V. Pistoia, S. Ferrini (2001)
Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression.Tissue antigens, 57 2
Current multimodal treatments for patients with neuroblastoma (NBL), including anti‐disialoganglioside (GD2) monoclonal antibody (mAb) based immunotherapy, result in a favorable outcome in around only half of the patients with advanced disease. To improve this, novel immunocombinational strategies need to be developed and tested in autologous preclinical NBL models. A genetically well‐explored autologous mouse model for NBL is the TH‐MYCN model. However, the immunobiology of the TH‐MYCN model remains largely unexplored. We developed a mouse model using a transplantable TH‐MYCN cell line in syngeneic C57Bl/6 mice and characterized the immunobiology of this model. In this report, we show the relevance and opportunities of this model to study immunotherapy for human NBL. Similar to human NBL cells, syngeneic TH‐MYCN‐derived 9464D cells endogenously express the tumor antigen GD2 and low levels of MHC Class I. The presence of the adaptive immune system had little or no influence on tumor growth, showing the low immunogenicity of the NBL cells. In contrast, depletion of NK1.1+ cells resulted in enhanced tumor outgrowth in both wild‐type and Rag1−/− mice, showing an important role for NK cells in the natural anti‐NBL immune response. Analysis of the tumor infiltrating leukocytes ex vivo revealed the presence of both tumor associated myeloid cells and T regulatory cells, thus mimicking human NBL tumors. Finally, anti‐GD2 mAb mediated NBL therapy resulted in ADCC in vitro and delayed tumor outgrowth in vivo. We conclude that the transplantable TH‐MYCN model represents a relevant model for the development of novel immunocombinatorial approaches for NBL patients.
International Journal of Cancer – Wiley
Published: Mar 15, 2015
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.